论文部分内容阅读
目的:分析346例脑梗死患者静脉用药情况,为脑梗死患者合理选用静脉用药物提供参考。方法:选取2012年1月—2013年2月间医院脑病科收治的脑梗死患者346例病历资料,统计患者的基本信息和静脉用药情况,以限定日剂量(DDD)计算用药频度(DDDs)和日均费用(DDDc)。结果:346例脑梗死患者静脉用药金额排序前3位的药物类型为中枢神经系统药物、中成药和抗感染药物,其中奥扎格雷钠在脑梗死患者静脉用药金额排序中居第3位,其DDDs排序靠前,具有疗效好、用药金额在患者可接受范围内和经济学属性佳的特点;乙酰谷酰胺的DDDs值为最大,DDDc值为最小,该药的经济学和药物治疗学属性均较为理想,为医院最常用的脑梗死患者辅助治疗药物;依达拉奉的用药金额、DDDc排序均居第1位,其用于治疗脑梗死的疗效较为显著,但经济学属性欠佳;单唾液酸四己糖神经节苷脂的用药金额、DDDs排序均居第2位,其DDDc值较大,价格较高,药物经济学属性不佳。结论:346例脑梗死患者的总有效率为97.11%,提示治疗用药和病情基本匹配,但由于脑梗死患者病情的复杂性,需多种药物联用治疗,因此临床应根据患者的疾病特点,合理选用静脉用药物。
Objective: To analyze the situation of intravenous medication in 346 patients with cerebral infarction, and to provide reference for rational use of intravenous drug in patients with cerebral infarction. Methods: A total of 346 cases of patients with cerebral infarction admitted from January 2012 to February 2013 in our hospital were enrolled in this study. The patients’ basic information and intravenous drug use were collected. DDDs were calculated according to daily dose (DDD) And average daily expenses (DDDc). Results: Among the 346 patients with cerebral infarction, the top three medications were CNS drugs, proprietary Chinese medicines and anti-infective drugs. Among them, ozagrel sodium ranks the third in the order of the amount of intravenous drugs used in patients with cerebral infarction. DDDs Ranking front, with good efficacy, the amount of medication within the acceptable range of patients and good economic properties; acetyl glutamine DDDs value is the largest, DDDc value is the smallest, the medicine’s economics and pharmacotherapy properties are more Ideal for the hospital most commonly used in patients with adjuvant therapy of cerebral infarction; edaravone medication amount, DDDc rank first place, its efficacy for the treatment of cerebral infarction is more significant, but poor economics attributes; single saliva The amount of acid tetrahexose ganglioside medication, DDDs rank second, DDDc value is larger, the higher the price, the poor economic properties of the drug. Conclusion: The total effective rate of patients with cerebral infarction is 97.11%, suggesting that the treatment and the disease basically match, but due to the complexity of the disease in patients with cerebral infarction, multi-drug combination therapy is required, so the clinical should be based on the patient’s disease characteristics, Rational use of intravenous drugs.